OA, OK?

How far has open access come in a decade? And where will it go in the next?

Written byRichard Gallagher
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

A decade ago, science publishing was in turmoil. In a petition backed by threats of boycotts of publishers who didn't play ball, many thousands of researchers demanded full and free online access to the literature. Stephen Harnad, one of the agents of change then and now, made the bold forecast that "The final state toward which the learned journal literature is evolving ... is as inevitable as it is optimal: Sooner or later, the entire corpus will be fully and freely accessible and navigable from the desk of any thinker in the world."

Well, we're still waiting. Harnad's 1998 prediction can be freely read today only because it was reproduced in an online forum (www.princeton.edu/~harnad/nature.html); the original version that Nature published1 requires a paid subscription to read. Today only a small fraction of the literature meets the criteria of open access, which Wikipedia defines as the "free, immediate, permanent, full-text, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies